About Pharma Industry

BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.

Millions Take Aspirin to Prevent Heart Attacks Based on a Typo; "Immodest" Bayer Site Not Helping

By Jim Edwards | Dec 11, 2009

Millions of people are needlessly popping an aspirin every day in the false belief that it will ward off heart attacks and strokes, according to HeartWire. In part, beliefs about the cardiovascular power of aspirin may have been spurred by a typo in an influential 2002 BMJ paper which originally said “daily aspirin may well be appropriate.” That final word should have been “inappropriate.” A correction was made, but not before the media began reporting on the heart-healthy benefits of daily aspirin.

HeartWire notes:

… a steady stream of studies have warned against aspirin use in some of the key primary-prevention populations, including patients with asymptomatic atherosclerosis, type 2 diabetes, and peripheral artery disease.

Most striking of all was the May 2009 meta-analysis, … The Lancet paper found that while aspirin used for primary prevention may reduce the risk of nonfatal ischemic events, these benefits are offset by higher bleeding, leaving no net effect on vascular mortality.

Dr. Eric Topol of Scripps Clinic La Jolla, Calif., adds:

… now there are, just in this country alone, literally tens of millions of people taking low-dose aspirin that probably there is no basis for.

… It’s really become kind of a consumer norm. As an outgrowth of the BMJ study in particular, aspirin has been advocated widely in the media. It’s not just the cardiologists and family doctors who are making recommendations, it’s magazines and newspapers and websites. It’s all over the place.”

The 2002 BMJ article, as originally printed, argued for some heart benefits of aspirin but not for all patients. It said, including the typo:

For most healthy individuals, however, for whom the risk of a vascular event is likely to be substantially less than 1% a year, daily aspirin may well be appropriate.” A correction swiftly issued by the BMJ noted that final word should, in fact, be inappropriate.

HeartWire also calls out Bayer (BAY.DE)’s web site for aspirin, which it calls “an immodest homepage for a drug that, at least in the primary-prevention arena, has weathered a less-than-wonderful year.” The site is indeed over the top and perhaps should be examined by the FDA for accuracy. Among the headlines:

  • “Expect Wonders”
  • “Heart Health Advantage”
  • “You Can Do More to Protect Your Heart!”

The site says aspirin can prevent stroke and heart attack, describing it as a “miracle drug.” It continues, “Aspirin has unsurpassed ability to fight pain and, used under a doctor’s care, can treat inflammation.” Unsurpassed? really? “Plus, it is the only analgesic that can help save your life when taken as directed by a doctor during a suspected heart attack.”

Bayer has a history of mismarketing aspirin. In October 2008 the FDA cited Bayer for marketing unapproved aspirin drugs, one of which was Bayer Aspirin With Heart Advantage.

Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Follow him on Twitter or send him an email.

BNET User Analysis

Web Buzz:
  • Omnicom, WPP big winners in Bayer agency consolidation

    Medical Marketing and Media - 31 days 15 hours 36 minutes ago

    Bayer announced today that it will split global advertising duties between Omnicom and WPP, a consolidation process set to be completed over the next two years. Account duties at WPP will be shared between Ogilvy & Mather and JWT. At Omnicom, BBDO Worldwide and CDM will serve as lead agencies, according to an emailed statement from Bayer. The...

  • Women suing Bayer over birth control pills

    Toronto Sun - 3 days 20 hours 3 minutes ago

    A group of Canadian women is suing the makers of popular birth control pills Yaz and Yasmin. CTV News reports the women claim they were not adequately warned about a higher than usual risk for stroke and other health problems before using the drugs. Yaz and Yasmin, made by Bayer’s Inc., are oral contraceptives that are used by thousands of...

  • ZymoGenetics, Inc. Q4 2009 Earnings Call Transcript

    Seeking Alpha - 31 days 8 hours 14 minutes ago

    We will now be conducting a question-and-answer session. (Operator Instructions). Our first question comes from the line of Howard Liang with Leerink Swann. Howard Liang - Leerink Swann First question on RECOTHROM sales in Q4, if we take out the sales to Bayer for Canada, it seems like ramp] is maybe little bit slowing; I was wondering is that...

  • Bayer shares plunge on poor 2009 results - Yahoo! News

    PharmaGossip - 17 days 1 hour 55 minutes ago

    Shares in the German pharmaceutical group Bayer, maker of Aspirin, plunged Friday after the group reported poor 2009 results amid what it called a difficult environment. via news.yahoo.com Posted via web from Jack's posterous

  • Bayer Consolidates Global Ad Business With Omnicom, WPP

    Ad Age - 31 days 19 hours 23 minutes ago

    NEW YORK (AdAge.com) -- German pharmaceutical giant Bayer AG today said it has consolidated its $850 million global advertising account with Omnicom Group and WPP. The review, which began in the summer of 2009, streamlines Bayer's agency relationships -- it was working with some 400 disparate agencies around the world -- and is expected to...

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a>)

advertisement
Click Here
advertisement
advertisement